A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT ID: NCT01427283

Last Updated: 2015-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to assess the efficacy of oxycodone/naloxone controlled-release tablets (OXN) for the management of opioid-induced constipation (OIC) compared with oxycodone controlled-release tablets (OXY) in subjects with moderate to severe low back pain and opioid-induced constipation who require around-the-clock opioid therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OXN

Oxycodone/Naloxone controlled-release tablets (OXN)

Group Type EXPERIMENTAL

Oxycodone/Naloxone controlled-release

Intervention Type DRUG

Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours

OXY

Oxycodone HCl controlled-release tablets (OXY)

Group Type ACTIVE_COMPARATOR

Oxycodone HCl controlled-release

Intervention Type DRUG

Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours

Placebo

Placebo tablets to match OXN or OXY

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo tablets to match OXN or OXY taken orally every 12 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxycodone/Naloxone controlled-release

Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours

Intervention Type DRUG

Oxycodone HCl controlled-release

Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours

Intervention Type DRUG

Placebo

Placebo tablets to match OXN or OXY taken orally every 12 hours

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OxyContin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects ≥ 18 years of age with moderate to severe, chronic low back pain (lasting at least several hours daily) as their predominant pain condition for at least 3 months prior to screening period;
* The low back pain must be related to nonmalignant and nonneuropathic conditions and may be with or without radiation;
* Subjects must have a self-reported history of opioid induced constipation (OIC).

Exclusion Criteria

* Subjects with rheumatoid arthritis or other inflammatory arthritis;
* Subjects with neuropathic conditions that have been painful or required therapy within the past 3 months;
* Subjects with evidence of significant structural abnormalities of the gastrointestinal (GI) tract or other significant conditions affecting GI motility;
* Subjects with chronic constipation not related to opioid use;
* Subjects who had surgical procedures directed towards the source of chronic low back pain within 6 months of the screening visit or planned during the study;
* Subjects with a history of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Purdue Pharma LP

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Investigational Site

Alabaster, Alabama, United States

Site Status

Investigational Site

Birmingham, Alabama, United States

Site Status

Investigational Site

Birmingham, Alabama, United States

Site Status

Investigational Site

Foley, Alabama, United States

Site Status

Investigational Site

Mobile, Alabama, United States

Site Status

Investigational Site

Mesa, Arizona, United States

Site Status

Investigational Site

Phoenix, Arizona, United States

Site Status

Investigational Site

Phoenix, Arizona, United States

Site Status

Investigational Site

Sun Lakes, Arizona, United States

Site Status

Investigational Site

Tucson, Arizona, United States

Site Status

Investigational Site

Tucson, Arizona, United States

Site Status

Investigational Site

Little Rock, Arkansas, United States

Site Status

Investigational Site

Sherwood, Arkansas, United States

Site Status

Investigational Site

Anaheim, California, United States

Site Status

Investigational Site

Anaheim, California, United States

Site Status

Investigational Site

Artesia, California, United States

Site Status

Investigational Site

Cerritos, California, United States

Site Status

Investigational Site

Chino, California, United States

Site Status

Investigational Site

El Cajon, California, United States

Site Status

Investigational Site

Encino, California, United States

Site Status

Investigational Site

Fountain Valley, California, United States

Site Status

Investigational Site

Fresno, California, United States

Site Status

Investigational Site

Garden Grove, California, United States

Site Status

Investigational Site

Garden Grove, California, United States

Site Status

Investigational Site

Laguna Hills, California, United States

Site Status

Investigational Site

Lakewood, California, United States

Site Status

Investigational Site

Lincoln, California, United States

Site Status

Investigational Site

Lomita, California, United States

Site Status

Investigational Site

Long Beach, California, United States

Site Status

Investigational Site

Oceanside, California, United States

Site Status

Investigational Site

Orange, California, United States

Site Status

Investigational Site

Paramount, California, United States

Site Status

Investigational Site

Sacramento, California, United States

Site Status

Investigational Site

San Bernardino, California, United States

Site Status

Investigational Site

San Diego, California, United States

Site Status

Investigational Site

San Diego, California, United States

Site Status

Investigational Site

Thousand Oaks, California, United States

Site Status

Investigational Site

Torrance, California, United States

Site Status

Investigational Site

Colorado Springs, Colorado, United States

Site Status

Investigational Site

Colorado Springs, Colorado, United States

Site Status

Investigational Site

Denver, Colorado, United States

Site Status

Investigational Site

Golden, Colorado, United States

Site Status

Investigational Site

Aventura, Florida, United States

Site Status

Investigational Site

Bradenton, Florida, United States

Site Status

Investigational Site

Chiefland, Florida, United States

Site Status

Investigational Site

Clermont, Florida, United States

Site Status

Investigational Site

Daytona Beach, Florida, United States

Site Status

Investigational Site

DeLand, Florida, United States

Site Status

Investigational Site

Edgewater, Florida, United States

Site Status

Investigational Site

Fort Lauderdale, Florida, United States

Site Status

Investigational Site

Fort Myers, Florida, United States

Site Status

Investigational Site

Hialeah, Florida, United States

Site Status

Investigational Site

Hialeah, Florida, United States

Site Status

Investigational Site

Inverness, Florida, United States

Site Status

Investigational Site

Jacksonville, Florida, United States

Site Status

Investigational Site

Jacksonville, Florida, United States

Site Status

Investigational Site

Jacksonville, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami, Florida, United States

Site Status

Investigational Site

Miami Beach, Florida, United States

Site Status

Investigational Site

Naples, Florida, United States

Site Status

Investigational Site

Naples, Florida, United States

Site Status

Investigational Site

New Smyrna Beach, Florida, United States

Site Status

Investigational Site

North Miami, Florida, United States

Site Status

Investigational Site

Oldsmar, Florida, United States

Site Status

Investigational Site

Orlando, Florida, United States

Site Status

Investigational Site

Oviedo, Florida, United States

Site Status

Investigational Site

Plantation, Florida, United States

Site Status

Investigational Site

Tamarac, Florida, United States

Site Status

Investigational Site

Tampa, Florida, United States

Site Status

Investigational Site

West Palm Beach, Florida, United States

Site Status

Investigational Site

Atlanta, Georgia, United States

Site Status

Investigational Site

Austell, Georgia, United States

Site Status

Investigational Site

Snellville, Georgia, United States

Site Status

Investigational Site

Boise, Idaho, United States

Site Status

Investigational Site

Boise, Idaho, United States

Site Status

Investigational Site

Chicago, Illinois, United States

Site Status

Investigational Site

Chicago, Illinois, United States

Site Status

Investigational Site

Chicago, Illinois, United States

Site Status

Investigational Site

Evansville, Indiana, United States

Site Status

Investigational Site

Indianapolis, Indiana, United States

Site Status

Investigational Site

Michigan City, Indiana, United States

Site Status

Investigational Site

Wichita, Kansas, United States

Site Status

Investigational Site

Edgewood, Kentucky, United States

Site Status

Investigational Site

Lake Charles, Louisiana, United States

Site Status

Investigational Site

Monroe, Louisiana, United States

Site Status

Investigational Site

New Orleans, Louisiana, United States

Site Status

Investigational Site

Pikesville, Maryland, United States

Site Status

Investigational Site

Brockton, Massachusetts, United States

Site Status

Investigational Site

Worcester, Massachusetts, United States

Site Status

Investigational Site

Florissant, Missouri, United States

Site Status

Investigational Site

Las Vegas, Nevada, United States

Site Status

Investigational Site

Atco, New Jersey, United States

Site Status

Investigational Site

Great Neck, New York, United States

Site Status

Investigational Site

Kew Gardens, New York, United States

Site Status

Investigational Site

New York, New York, United States

Site Status

Investigational Site

Rochester, New York, United States

Site Status

Investigational Site

Williamsville, New York, United States

Site Status

Investigational Site

Durham, North Carolina, United States

Site Status

Investigational Site

Elkin, North Carolina, United States

Site Status

Investigational Site

High Point, North Carolina, United States

Site Status

Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Investigational Site

Columbus, Ohio, United States

Site Status

Investigational Site

Dayton, Ohio, United States

Site Status

Investigational Site

Moraine, Ohio, United States

Site Status

Investigational Site

Toledo, Ohio, United States

Site Status

Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Investigational Site

Eugene, Oregon, United States

Site Status

Investigational Site

Jenkintown, Pennsylvania, United States

Site Status

Investigational Site

Levittown, Pennsylvania, United States

Site Status

Investigational Site

Mechanicsburg, Pennsylvania, United States

Site Status

Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Investigational Site

Red Lion, Pennsylvania, United States

Site Status

Investigational Site

State College, Pennsylvania, United States

Site Status

Investigational Site

Warwick, Rhode Island, United States

Site Status

Investigational Site

Charleston, South Carolina, United States

Site Status

Investigational Site

Myrtle Beach, South Carolina, United States

Site Status

Investigational Site

Rapid City, South Dakota, United States

Site Status

Investigational Site

Jackson, Tennessee, United States

Site Status

Investigational Site

Allen, Texas, United States

Site Status

Investigational Site

Austin, Texas, United States

Site Status

Investigational Site

Dallas, Texas, United States

Site Status

Investigational Site

Dallas, Texas, United States

Site Status

Investigational Site

Dallas, Texas, United States

Site Status

Investigational Site

Dallas, Texas, United States

Site Status

Investigational Site

Houston, Texas, United States

Site Status

Investigational Site

Houston, Texas, United States

Site Status

Investigational Site

Houston, Texas, United States

Site Status

Investigational Site

Houston, Texas, United States

Site Status

Investigational Site

McKinney, Texas, United States

Site Status

Investigational Site

North Richland Hills, Texas, United States

Site Status

Investigational Site

Tomball, Texas, United States

Site Status

Investigational Site

Orem, Utah, United States

Site Status

Investigational Site

Salt Lake City, Utah, United States

Site Status

Investigational Site

Salt Lake City, Utah, United States

Site Status

Investigational Site

Danville, Virginia, United States

Site Status

Investigational Site

Midlothian, Virginia, United States

Site Status

Investigational Site

Richmond, Virginia, United States

Site Status

Investigational Site

Bothell, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-005061-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ONU3705

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Buprenorphine Naltrexone-P1 A-Cocaine
NCT00733720 COMPLETED PHASE1